Compare Progressive Corp (PGR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Progressive Corp trades at $215.8 (market cap $125.23B), while Vertex Pharmaceuticals Incorporated trades at $520 (market cap $134.06B). The key difference: Progressive Corp and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Progressive Corp pays a 0.19% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PGR | VRTX | |
|---|---|---|
Market Cap | $125.23B | $134.06B |
Sector | Financials | Health |
52-Week High | $248.80 | $557.96 |
52-Week Low | $190.40 | $376.62 |
Enterprise Value | $133.44B | $128.18B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive (PGR) trades at $214.9, down 1.85% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and ROE of 34.94%, supported by revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q4 2025 and Q2 2026, but missed in Q1 2026. News highlights competition in auto insurance and telematics advantages.
Outlook is mixed: analyst consensus targets $231.18 with 38.1% buy ratings, but technical weakness and competitive pressures pose risks. Investment opportunity lies in valuation discounts and operational strength, though expense increases and market volatility require caution.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
